IL-15 in the Combination Immunotherapy of Cancer
We completed clinical trials of rhIL-15 by bolus, subcutaneous, and continuous intravenous infusions (CIV). IL-15 administered by CIV at 2 mcg/kg/day yielded a 38-fold increase in 10- day number of circulating NK cells, a 358-fold increase in CD56bright NK cells and a 5.8-fold increase in CD8 T cell...
| Những tác giả chính: | , , , |
|---|---|
| Định dạng: | Bài viết |
| Ngôn ngữ: | English |
| Được phát hành: |
Frontiers Media S.A.
2020-05-01
|
| Loạt: | Frontiers in Immunology |
| Những chủ đề: | |
| Truy cập trực tuyến: | https://www.frontiersin.org/article/10.3389/fimmu.2020.00868/full |